Format

Send to

Choose Destination
Oncotarget. 2016 Jul 5;7(27):41172-41185. doi: 10.18632/oncotarget.9226.

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.

Author information

1
INSERM U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
2
CNRS 6299, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
3
OGD2 Pharma, Institut de Recherche en Santé de l'Université de Nantes, Nantes, France.
4
Université de Nantes, UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France.
5
Centre Hospitalier Universitaire de Nantes, Nantes, France.
6
LaBCT, Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France.

Abstract

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

KEYWORDS:

ganglioside; glioblastoma; immunotherapy

PMID:
27172791
PMCID:
PMC5173050
DOI:
10.18632/oncotarget.9226
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center